摘要
随着中国新冠病毒疫情的缓解,全国各地逐步进入一个低传播或无传播阶段。尽管局部和零星的疫情爆发依旧是一个实际存在的可能,但是通过前期抗疫中积累的医疗和流行性疾病管理经验,以及全国上下对这类病毒流行的高度警惕和防备,目前和未来可能的疫情变化应该是“可防可控”的。根据国内外专家的预测新型冠状病毒极有可能将长期与人类共存并将呈现季节性或不定期的复发,因此建立人群对于新冠病毒的免疫力是一个关键性和根本性的防御措施。目前世界各国都在积极研发针对这次新冠病毒的疫苗,以期通过普遍接种疫苗达到有效“群体免疫”。本文介绍了目前几类主要的疫苗研发技术平台,并对于不同技术平台和产品的优势和劣势进行了初步的比较和分析,为正在与时间竞赛,积极开展新冠疫苗的研究人员提供一些建议和思路。
With the rapid alleviation of the new coronavirus epidemic,China has progressed into a stage of low or no viral transmission.Although local and sporadic outbreaks are still a real possibility,with the valuable medical treatment and public epidemic management experience,as well as the high vigilance and preparedness of the entire country,potential future outbreak should be“preventable and manageable”.According to experts from home and abroad,the novel coronavirus will likely to exist within human communities for a long time with seasonal or sporadic recurrence.Therefore,a critical and essential defense measure to prevent next epidemic is to establish broad immunity within large population against the new coronavirus.At present,countries around the world are aggressively developing vaccines against the new coronavirus,in order to build up so-called“Herd Immunity”through vaccination.In this review,the author discussed several vaccine development technology platforms and compared the advantages and disadvantages of these platforms and their products,in a hope to provide useful thoughts and suggestions for scientists who are fiercely developing novel vaccines against time.
作者
王建新
李谦
WANG Jian-xin;LI Qian(ImmuOn Therapeutics Ltd,Nantong,226000,China;School of Life Science&Biotechnology,China Pharmaceutical University,Nanjing 210009,China)
出处
《药物生物技术》
CAS
2020年第1期8-13,共6页
Pharmaceutical Biotechnology
基金
国家自然科学基金项目(No.81630092)
江苏省基金项目(No.BK20171202)
常州市基金项目(No.CJ20180013)。
关键词
新冠病毒
疫苗
群体免疫
New coronavirus
Vaccine
Herd Immunity
